

Referenze scientifiche:

1. Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL, Griffith M. *Best practices for bioinformatic characterization of neoantigens for clinical utility*. Genome Medicine. 2019;11:56. DOI: 10.1186/s13073-019-0666-2.
2. Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. *Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study*. Lancet. 2024;403(10427):632–644. doi: 10.1016/S0140-6736(23)02268-7.
3. Khattak A, Carlino MS, Meniawy T, Ansstas G, Taylor MH, Kim KB, et al. *Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase 2b KEYNOTE-942 study*. J Clin Oncol. 2026 Jun 1. doi: 10.1200/JCO-26-00835. Epub ahead of print.
4. Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. *Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer*. Nature. 2023;618:144–150. doi: 10.1038/s41586-023-06063-y.
5. ClinicalTrials.gov. *A study of pembrolizumab with or without intismeran autogene (V940) in participants with non-small cell lung cancer (V940-009/INTerpath-009)* [Internet]. Identificativo NCT06623422. Bethesda (MD): National Library of Medicine (US); 2024 [consultato il 2 settembre 2026]. Disponibile su: <https://clinicaltrials.gov/study/NCT06623422>